Repligen Corp
NASDAQ:RGEN

Watchlist Manager
Repligen Corp Logo
Repligen Corp
NASDAQ:RGEN
Watchlist
Price: 146.74 USD 0.47% Market Closed
Market Cap: 8.2B USD
Have any thoughts about
Repligen Corp?
Write Note

Repligen Corp
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Repligen Corp
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Repligen Corp
NASDAQ:RGEN
Pre-Tax Income
$4.9m
CAGR 3-Years
-67%
CAGR 5-Years
-30%
CAGR 10-Years
-11%
Thermo Fisher Scientific Inc
NYSE:TMO
Pre-Tax Income
$6.8B
CAGR 3-Years
-12%
CAGR 5-Years
11%
CAGR 10-Years
13%
Danaher Corp
NYSE:DHR
Pre-Tax Income
$4.1B
CAGR 3-Years
-17%
CAGR 5-Years
7%
CAGR 10-Years
2%
Mettler-Toledo International Inc
NYSE:MTD
Pre-Tax Income
$955.2m
CAGR 3-Years
1%
CAGR 5-Years
7%
CAGR 10-Years
8%
Agilent Technologies Inc
NYSE:A
Pre-Tax Income
$1.5B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Pre-Tax Income
$1.5B
CAGR 3-Years
17%
CAGR 5-Years
33%
CAGR 10-Years
12%
No Stocks Found

Repligen Corp
Glance View

Market Cap
8.2B USD
Industry
Life Sciences Tools & Services

Repligen Corp., a prominent player in the bioprocessing industry, has carved out a niche that centers on providing high-quality bioprocessing solutions for the production of biologics, particularly therapeutic proteins and monoclonal antibodies. Founded in 1981 and headquartered in Waltham, Massachusetts, Repligen has transformed itself from a developer of research tools into a critical partner for biopharmaceutical manufacturers. The company is primarily engaged in producing innovative products that enhance the efficiency and effectiveness of biomanufacturing processes. Its offerings range from filtration systems to cell culture media, all designed to accelerate drug development and ensure consistent product quality. Through strategic acquisitions and partnerships, Repligen has expanded its portfolio and technological capabilities, positioning itself as a leading provider in a high-demand market driven by the growing need for biologic therapies. For investors, Repligen represents a compelling opportunity rooted in its impressive growth trajectory and strong financial performance. The company has consistently reported rising revenues, bolstered by the increasing global demand for biologics and bioprocessing innovations. Repligen’s continuous investment in research and development ensures that it remains at the forefront of technological advancements, while its robust customer base includes some of the world’s leading pharmaceutical and biotech companies. With a strong balance sheet and a commitment to operational excellence, Repligen is poised for sustainable growth in an industry that is expected to expand significantly over the coming years. For those seeking exposure to the booming biopharmaceutical sector, Repligen offers a unique position that balances innovation, growth potential, and strategic leadership.

RGEN Intrinsic Value
70.27 USD
Overvaluation 52%
Intrinsic Value
Price

See Also

What is Repligen Corp's Pre-Tax Income?
Pre-Tax Income
4.9m USD

Based on the financial report for Sep 30, 2024, Repligen Corp's Pre-Tax Income amounts to 4.9m USD.

What is Repligen Corp's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-11%

Over the last year, the Pre-Tax Income growth was -96%. The average annual Pre-Tax Income growth rates for Repligen Corp have been -67% over the past three years , -30% over the past five years , and -11% over the past ten years .

Back to Top